As per the report, Biocon Biologics Limited, which focuses on biosimilars, is particularly exposed with about 40 per cent of ...

A Fitch Wire report said that while Indian corporates generally have low direct exposure to current US tariffs, the ...

MUMBAI: Fitch Ratings has cautioned that while Indian corporates currently face limited direct exposure to recent US tariff ...

Shaw, Executive Chairperson of Biocon & Biocon Biologics, said the pharma industry faces long 'lab-to-market' timelines, high ...

Prime Minister Narendra Modi on Friday asked scientists and entrepreneurs to focus more on research and development (R&D), ...

Vana Charitable Trust partners with Syngene Biocon Foundation to restore mangroves along Netravathi riverbank in Mangaluru.

Biocon Limited ( ($IN:BIOCON) ) has provided an update. Biocon Limited has released the transcript of its Q1 FY26 earnings call, which was held on ...

The company is also focused on strategic capital deployment. It has already invested in GLP-1 drug substance and drug product ...

ICICI Securities is bearish on Biocon has recommended sell rating on the stock with a target price of Rs 270 in its research report dated August 09, 2025.

Biocon Ltd (BOM:532523) reports a robust 15% increase in operating revenue, driven by biosimilars and CRDMO growth, despite facing margin pressures and increased interest expenses.

Biocon gears up to ride weight-loss drug boom to script next growth chapter Managing director & CEO Siddharth Mittal says is de-risking supply chain as Trump tariffs loom.